Biotech Platform Technologies: Oncotelic Leads AI-Driven Drug Delivery Revolution

Biotechnology companies are increasingly turning to advanced drug-delivery technologies, nanotechnology platforms, and artificial intelligence to enhance existing therapies and expand treatment opportunities, according to a recent BioMedWire editorial. The article highlights Oncotelic Therapeutics (OTCQB: OTLC) as a key player in this trend, particularly through its Sapu003 program, Deciparticle(TM) platform, and PDAOAI initiative. These platforms are designed to support scalable, multi-application biotechnology programs in oncology and rare diseases, reflecting a broader industry shift toward platform technologies that can be adapted for multiple therapeutic uses.

The editorial also covers other notable biotech companies leveraging platform approaches. CytoDyn Inc. (OTCQB: CYDY) is advancing leronlimab for oncology indications, while Revolution Medicines Inc. (NASDAQ: RVMD) reported positive Phase 3 results for daraxonrasib in pancreatic cancer. Moderna Inc. (NASDAQ: MRNA) published positive Phase 3 data for its mRNA-1010 influenza vaccine candidate, and Sarepta Therapeutics Inc. (NASDAQ: SRPT) announced encouraging early clinical results from two neuromuscular disease programs. Together, these companies illustrate growing industry and investor interest in platform technologies that promise long-term innovation and multiple therapeutic applications.

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. Beyond internal programs, the company licenses and co-develops drug candidates through strategic partnerships, including a 45% interest in GMP Bio. The full press release is available at https://nnw.fm/HqBkN.